Updated Recommendations: The update emphasizes the need for changes in heart failure (HF) management based on over ten new randomized controlled trials published since the 2021 ESC Guidelines, focusing on chronic HF, acute HF, and comorbidities.

SGLT2 Inhibitors for Chronic HF: New recommendations advocate the use of sodium–glucose co-transporter 2 (SGLT2) inhibitors, specifically dapagliflozin or empagliflozin, for patients with mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF) to reduce hospitalization and cardiovascular death risk.

Terminology Consideration: Although there were discussions to redefine HFpEF as ‘HF with normal ejection fraction (HFnEF)’ and modify the left ventricular ejection fraction (LVEF) thresholds, the task force decided to retain the term ‘HFpEF’ for now.

Acute HF Management Enhancements: The STRONG-HF trial supports the initiation and rapid titration of oral HF therapies within two days before discharge, promoting high-intensity care and close follow-up in the first six weeks to decrease readmissions and mortality.

Addressing Comorbidities: New guidelines recommend dapagliflozin or empagliflozin for preventing HF in patients with chronic kidney disease (CKD) and type 2 diabetes (T2DM), along with finerenone for further risk reduction, based on recent trials.